Journal of magnetic resonance imaging : JMRI
-
J Magn Reson Imaging · Apr 2018
MRI proton density fat fraction is robust across the biologically plausible range of triglyceride spectra in adults with nonalcoholic steatohepatitis.
Proton density fat fraction (PDFF) estimation requires spectral modeling of the hepatic triglyceride (TG) signal. Deviations in the TG spectrum may occur, leading to bias in PDFF quantification. ⋯ 3 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2018;47:995-1002.
-
J Magn Reson Imaging · Apr 2018
Textural features of dynamic contrast-enhanced MRI derived model-free and model-based parameter maps in glioma grading.
Presurgical glioma grading by dynamic contrast-enhanced MRI (DCE-MRI) has unresolved issues. ⋯ 3 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2018;47:1099-1111.
-
J Magn Reson Imaging · Apr 2018
Reproducibility of in vivo magnetic resonance imaging T1 rho and T2 relaxation time measurements of hip cartilage at 3.0T in healthy volunteers.
To assess the T1 ρ and T2 values in the hip cartilage of healthy volunteers and to evaluate the reproducibility of these measurements. ⋯ 2 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2018;47:1022-1033.
-
J Magn Reson Imaging · Apr 2018
Solid bone tumors of the spine: Diagnostic performance of apparent diffusion coefficient measured using diffusion-weighted MRI using histology as a reference standard.
To assess the diagnostic performance of mean apparent diffusion coefficient (mADC) in differentiating benign from malignant bone spine tumors, using histology as a reference standard. Conventional magnetic resonance imaging (MRI) sequences have good reliability in evaluating spinal bone tumors, although some features of benign and malignant cancers may overlap, making the differential diagnosis challenging. ⋯ 3 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2018;47:1034-1042.
-
J Magn Reson Imaging · Apr 2018
Intravoxel incoherent motion diffusion-weighted imaging in assessing bladder cancer invasiveness and cell proliferation.
Nonmuscle-invasive bladder cancer (NMIBC, Stage T1 or lower) is treated with transurethral resection (TUR), while muscle-invasive bladder cancer (MIBC, Stage T2 or more) requires neoadjuvant chemotherapy before radical cystectomy. Hence, preoperative differentiation is vital. ⋯ 1 Technical Efficacy: Stage 3 J. Magn. Reson. Imaging 2018;47:1054-1060.